Literature DB >> 8936753

One-session group treatment of spider phobia.

L G Ost1.   

Abstract

Forty-two patients with spider phobia, fulfilling the DSM-III-R criteria for simple phobia, were assessed with behavioral, physiological and self-report measures. They were randomly assigned to two group treatment conditions: (1) small groups of three to four patients, and (2) large groups of seven to eight patients. They received one 3-hr session consisting of exposure and modeling. The results showed that both conditions yielded significant improvements on almost all measures, and these were maintained or furthered at the 1-yr follow-up. With one exception, there was no difference between the conditions, but on most measures there was a trend for the small group condition to yield better effects. The proportions of clinically significantly improved patients at post-treatment were 82% in the small group and 70% in the large group. At follow-up the corresponding figures were 95% and 75%, respectively. The conclusion that can be drawn is that one-session group treatment is a feasible alternative to individual treatment, yielding almost as good effects.

Entities:  

Mesh:

Year:  1996        PMID: 8936753     DOI: 10.1016/0005-7967(96)00022-8

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  15 in total

Review 1.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

Authors:  Stefan G Hofmann; Mark H Pollack; Michael W Otto
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  The assessment and treatment of specific phobias: a review.

Authors:  Daniel F Grös; Martin M Antony
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

Review 3.  Neurobiological correlates of cognitions in fear and anxiety: a cognitive-neurobiological information-processing model.

Authors:  Stefan G Hofmann; Kristen K Ellard; Greg J Siegle
Journal:  Cogn Emot       Date:  2011-08-01

4.  Symptom provocation and reduction in patients suffering from spider phobia: an fMRI study on exposure therapy.

Authors:  Anne Schienle; Axel Schäfer; Andrea Hermann; Sonja Rohrmann; Dieter Vaitl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

5.  Large Group Exposure Treatment: a Feasibility Study in Highly Spider Fearful Individuals.

Authors:  André Wannemueller; David Appelbaum; Maike Küppers; Amelie Matten; Tobias Teismann; Dirk Adolph; Jürgen Margraf
Journal:  Front Psychol       Date:  2016-08-09

6.  Large Group Exposure Treatment: A Feasibility Study of Exposure Combined with Diaphragmatic Breathing in Highly Dental Fearful Individuals.

Authors:  André Wannemueller; Hans-Peter Jöhren; Alina Borgstädt; Jessica Bosch; Milena Meyers; Miriam Völse; Saskia Scholten; Jürgen Margraf
Journal:  Front Psychol       Date:  2017-01-06

7.  Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric external cross-validation machine learning approach.

Authors:  Hanna Schwarzmeier; Elisabeth Johanna Leehr; Joscha Böhnlein; Fabian Reinhard Seeger; Kati Roesmann; Bettina Gathmann; Martin J Herrmann; Niklas Siminski; Markus Junghöfer; Thomas Straube; Dominik Grotegerd; Udo Dannlowski
Journal:  Int J Methods Psychiatr Res       Date:  2019-12-08       Impact factor: 4.035

Review 8.  Why Do We Need Computational Models of Psychological Change and Recovery, and How Should They Be Designed and Tested?

Authors:  Warren Mansell; Vyv Huddy
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

Review 9.  Family treatment of child anxiety: outcomes, limitations and future directions.

Authors:  Cathy Creswell; Sam Cartwright-Hatton
Journal:  Clin Child Fam Psychol Rev       Date:  2007-09

10.  Re-presentation of Olfactory Exposure Therapy Success Cues during Non-Rapid Eye Movement Sleep did not Increase Therapy Outcome but Increased Sleep Spindles.

Authors:  Julia S Rihm; Silja B Sollberger; Leila M Soravia; Björn Rasch
Journal:  Front Hum Neurosci       Date:  2016-06-30       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.